Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
March 21, 2024 at 02:14 pm IST
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 11,462.74 million compared to KRW 16,865.89 million a year ago. Net loss was KRW 20,707.56 million compared to net income of KRW 12,161.17 million a year ago.
Basic loss per share from continuing operations was KRW 763 compared to basic earnings per share from continuing operations of KRW 447 a year ago. Basic loss per share was KRW 763 compared to basic earnings per share of KRW 447 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 